The medicine is generally used across therapeutic domains involving symptoms related to heightened physiological activity, supporting patients during episodes of significant discomfort.

---

Management of Acute Psychosis and Thought Disorders

The medication may assist with managing symptoms that become more disruptive during flare-ups, such as hallucinations and delusions, in conditions like Schizophrenia in adults and adolescents. It generally contributes to easing the overall symptom load, and may help maintain a sense of stability when symptoms are more noticeable.

Stabilization of Bipolar Mood Episodes

Quetiapine is commonly used in conditions characterized by periods of heightened symptoms of Bipolar Disorder. It is applied in scenarios where additional management of discomfort is required for symptoms that become more disruptive during flare-ups of both acute manic episodes and major depressive episodes. This use is considered relevant for managing the risk of recurrent or episodic manifestations.

Adjunctive Support for Major Depression

The medication may be part of symptomatic management when used in combination with primary antidepressant therapy for adults experiencing Major Depressive Disorder (MDD) in situations where previous treatment response was incomplete. It contributes to improved comfort during periods of heightened symptoms and provides supportive relief when symptoms that interfere with daily functioning are present.

Quick Fact: Relief for symptoms that interfere with daily functioning is a key therapeutic focus, may assist with maintaining a sense of stability when symptoms are more noticeable.

The eligibility for Quetiapine use is strictly defined by regulatory authorities based on specific patient characteristics and clinical history.

Absolute Exclusions (Contraindications)

Quetiapine must not be used by individuals who have a known hypersensitivity to the medicine or its components. Use is also strictly contraindicated in patients concurrently taking potent inhibitors of the CYP3A4 enzyme, which includes certain antifungal and HIV protease inhibitor medications.

Age and Special Population Restrictions

The medicine is not approved for the treatment of psychosis related to dementia in older adults due to a documented increased risk of death. For pediatric use, safety and effectiveness are not established for most children under the age of 13. Older adults generally require careful monitoring and lower initial doses.

Conditional Use and Caution

Eligibility is conditional for patients with certain medical conditions. Individuals with known hepatic impairment (liver disease) should be treated with caution and typically require a reduced starting dose. Caution is also necessary for patients with a history of seizures or those with known cardiovascular or cerebrovascular disease. During pregnancy, use is allowed only when the potential benefit justifies the potential risk, and continued use during lactation requires a medical decision regarding discontinuing the drug or nursing.

Interactions with Other Medicines and Products

Quetiapine (Seroquel) has important documented interactions, primarily through its metabolism in the liver by the enzyme CYP3A4. These interactions can significantly affect the amount of quetiapine in the bloodstream.

• Strong CYP3A4 Inhibitors: Co-administration with strong inhibitors of this enzyme, such as certain antifungal agents (e.g., ketoconazole) or certain antivirals (e.g., ritonavir), increases quetiapine's plasma concentration. This may necessitate a dose reduction of quetiapine, potentially down to one-sixth of the usual dose, to minimize the risk of side effects.

• Strong CYP3A4 Inducers: Conversely, co-administration with strong enzyme inducers, such as phenytoin, rifampin, or St. John's wort, can markedly reduce quetiapine's concentration, potentially leading to a loss of treatment effect. In these cases, the quetiapine dose may need to be increased up to 5-fold. Dose adjustments are also required when discontinuing the inducer.

• Other Centrally Acting Drugs: Caution is advised when using quetiapine with other drugs that affect the central nervous system (CNS), including alcohol, benzodiazepines, or certain pain medications. This combination can increase the risk of side effects like excessive drowsiness, sedation, dizziness, or lowered blood pressure. The use of alcohol should be avoided.

• Grapefruit Juice: Consuming grapefruit or grapefruit juice should be discussed with a healthcare provider, as it can inhibit CYP3A4 and increase quetiapine levels.

Before starting quetiapine, patients must inform their healthcare professional about all prescription medications, over-the-counter products, vitamins, and herbal supplements they are currently taking.

Targeted Modulation of Neurotransmitter Systems

Quetiapine's mechanism centers on the antagonism (blocking) of key central nervous system receptors, specifically the Dopamine D2 and Serotonin 5-HT2A receptors. A distinguishing mechanistic feature is the drug's rapid dissociation (fast on-and-off binding) from the D2 receptor, which allows for signal modulation rather than sustained suppression. This selective dual action influences the activity of neural circuits, contributing to central nervous system equilibrium.

Metabolite-Mediated Pathway Influence

The mechanism is broadened by its active metabolite, norquetiapine. This metabolite acts as a partial agonist at the Serotonin 5-HT1A receptor and as an inhibitor of the Norepinephrine Transporter left(NET ight). This secondary action increases the concentration and signaling of norepinephrine and serotonin in the synapse. This dual-component mechanism contributes to the modulation of signaling within mood and cognitive pathways, complementing the parent drug's primary influence on receptor activity.

Secondary actions include antagonism at the Histamine H1 receptor, which influences central nervous system activity related to arousal centers, and antagonism at the Adrenergic alpha1 receptor, which modulates vascular tone.

Quetiapine is administered exclusively by the oral route as either an immediate-release (IR) tablet or an extended-release (XR) tablet.

Dosing Schedule and Frequency

Treatment is initiated using a low starting dose followed by a structured, gradual titration over the initial days to reach the established maintenance dose range. The maximum daily dose for most adult indications is 800 mg, though lower maximums apply to specific uses like Bipolar Depression (300 mg/day).

The frequency of administration depends on the formulation: IR tablets are generally taken in divided doses (typically two or three times daily), while XR tablets are administered once daily, preferably in the evening.

Administration Context and Adjustments

Contextual rules for proper administration vary by formulation. IR tablets may be taken with or without food. However, XR tablets must be taken without food or with a light meal (approximately 300 calories). Furthermore, XR tablets must be swallowed whole and must not be split, chewed, or crushed.

Specific dose modifications are mandated for certain populations. Older adults (geriatric use) and patients with hepatic impairment require a lower starting dose and a slower titration rate. The official regimen also requires dose reduction when quetiapine is used concurrently with strong CYP3A4 inhibitors. Treatment typically involves a short-term acute phase followed by a long-term maintenance phase.

Research evidence / Overview of studies for Сероквель

---

Evidence for Acute and Maintenance Studies in Schizophrenia

Quetiapine was studied for use in conditions characterized by severe thought disorders, and research explored the maintenance of symptom patterns over time. The main body of research includes numerous short-term, placebo-controlled Randomized Controlled Trials (RCTs). These studies were conducted during periods of increased symptom activity and research focused on how symptoms were measured using severity scales over defined time intervals, typically around six weeks.

Findings describe patterns observed in the studies related to measured changes in both positive symptoms and negative symptoms. Research monitored participant discontinuation rates, which provided insight into how patients reported their experience and contributed to understanding patterns of discontinuation in the trial setting. Longer-term maintenance studies were also conducted, and research describes patterns related to the time to recurrence of symptoms (relapse) in the studied populations.

---

Evidence for Bipolar Disorder: Manic and Depressive Episodes

Quetiapine was evaluated in conditions characterized by fluctuating or episodic manifestations, including both manic and major depressive episodes associated with Bipolar I and II Disorder. Studies examined how symptoms were measured during periods of increased symptom activity. The research explored both quetiapine as a single therapy and as an addition (adjunctive therapy) to other established mood stabilizers.

Findings describe patterns observed in acute changes measured during the study period. For the depressive phase, studies examined outcomes reflecting daily functioning or activity level, alongside measures of response and remission. Maintenance studies also monitored for the recurrence of any mood episode.

---

Research Gaps and Areas of Uncertainty

Evidence highlights what is known—and what is still uncertain. Findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly. Major limitations frequently documented include follow-up durations being limited in many acute studies, leading to a general lack of comprehensive data on long-term functional and cognitive outcomes. Data for certain groups, such as children and adolescents for long-term use, and older adults with specific mood disorders, remain insufficient.

Key Studies & References

1. NICE Guideline CG185: Bipolar disorder: assessment and management (Referenced for clinical context and treatment focus)
2. Quetiapine - StatPearls (Referenced for overview of FDA indications and trial outcomes)

Common questions about Сероквель (FAQ)

---

Q: How long does it usually take to feel the main effect of Сероквель?

The official documents indicate that the time to observe therapeutic effects can vary by condition. For example, in clinical studies for bipolar depression, an improvement in symptoms was noted as early as the first week of treatment. The drug substance reaches its highest concentration in the bloodstream in about 1.5 hours, and consistent therapeutic concentrations are typically observed within two days of consistent intake.

Q: Can I take Сероквель along with over-the-counter pain medications?

Official product information cautions that using this medicine alongside other drugs that affect the central nervous system, which may include certain pain medications, can increase the risk of side effects. These shared effects often include heightened drowsiness or sedation. It is described that caution is warranted when considering such combinations.

Q: What happens if a dose of Сероквель is missed?

Regulatory patient instructions state that a missed dose is taken as soon as possible. However, if it is almost time for the next scheduled dose, the missed dose is skipped entirely. Official guidance emphasizes that doses are not doubled to compensate for a missed one.

Q: Is taking Сероквель described as safe for patients who have glaucoma?

Official warnings note that this medicine has an anticholinergic effect, meaning it can influence certain involuntary body functions. Because of this action, caution may be necessary for individuals who have or are at risk for narrow-angle glaucoma.

Q: How does Сероквель affect prolactin levels?

Studies reviewed for the official product information have documented instances where an increase in prolactin levels was observed in some patients receiving this medicine. Prolactin is a hormone that can affect various body systems.

Q: What factors influence the time it takes for Сероквель to start working?

The body's processing of the drug, known as pharmacokinetics, is influenced by several factors. These include the specific dose being administered and whether the immediate-release or extended-release formulation is used. Additionally, the medicine’s processing is highly dependent on liver enzymes, meaning interactions with certain other medicines can alter how quickly or slowly it reaches therapeutic levels.

Q: Are there described interactions between Сероквель and thyroid medications?

Official clinical trial data indicate that a decrease in thyroid function, known as hypothyroidism, has been reported in some patients. Due to this finding, regulatory guidelines indicate that monitoring of thyroid function is typically recommended while the patient is receiving the medicine.

Q: Can Сероквель be used only when needed or does it require regular intake?

Official treatment regimens for all approved uses require the medication to be used on a scheduled, continuous basis. Treatment typically involves a low dose initiation, gradual adjustment, and a maintenance phase. The established structure of this regimen implies continuous intake rather than usage only when symptoms occur.

Q: What precautions are described when using Сероквель in hot weather?

Official patient guidelines describe the need for precautions to prevent the body from becoming overheated or dehydrated. When exposed to hot weather, the guidance describes staying in cool environments and maintaining sufficient water intake.

Q: Does Сероквель affect libido?

While changes in libido are not directly listed as a common effect in the official documentation, the product information does report adverse reactions involving hormone level alterations and conditions like priapism. These reported effects may be associated with changes in sexual function.

Q: Is the use of Сероквель associated with the risk of developing cataracts?

Official safety warnings note that lens changes, potentially leading to cataracts, have been observed in patients during long-term treatment. To monitor this possibility, regulatory recommendations describe that a lens examination may be warranted when starting treatment and at 6-month intervals during chronic use.

How to Store and Dispose of Seroquel (Quetiapine Fumarate)

The storage and disposal of Seroquel tablets must follow official regulatory requirements to maintain product integrity and ensure safety.

Storage Requirements

Seroquel must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The product should be kept in a cool, dry place and remain in its original, tightly closed container. To prevent accidental ingestion, the medication must be stored out of the sight and reach of children and pets.

Disposal Instructions

Unused or expired Seroquel should be disposed of by utilizing a drug take-back program. If this option is not available, the medication must be mixed with an unappealing substance, such as dirt or used coffee grounds, placed in a sealed bag, and discarded in the household trash. Seroquel is not recommended to be flushed down a toilet or sink.